Loading...
•
Sep 30, 2023
Nkarta Q3 2023 Earnings Report
Nkarta reported financial results for the third quarter ended September 30, 2023, expanded its NK cell therapy pipeline into autoimmune disease, and extended its projected cash runway into 2026.
Key Takeaways
Nkarta reported its Q3 2023 financial results, highlighting the expansion of its NK cell therapy pipeline into autoimmune disease with NKX019 and the extension of its projected cash runway into 2026 through cost containment measures. The company's pipeline now includes three clinical-stage NK cell therapy programs. First patient in the LN study is expected to be dosed in the first half of 2024.
FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune disease.
Multiple clinical pipeline updates planned for 2024 include NHL, AML and lupus nephritis.
Cost containment measures expected to extend Nkarta’s projected cash runway by one year into 2026.
Cash and cash equivalents of $278.4 million on September 30, 2023.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...